Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials

Authors

Institutions

Publication Details

Journal
Ophthalmology and Therapy
Published
2025-10-09
DOI
https://doi.org/10.1007/s40123-025-01255-3
Primary Topic
Ophthalmology and Eye Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials

Oluwatobi O. Idowu, Christopher Brittain, Daniel G. Ezra, Zdenka Hašková et al.
Ophthalmology and Therapy
Ophthalmology and Eye Disorders
article

Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials

Oluwatobi O. Idowu, Christopher Brittain, Daniel G. Ezra, Zdenka Hašková, Hiroaki Ida, A. Bernard Collins, Thomas Kuenzel, Miriam Triyatni
article en

Abstract

No abstract available for this paper.
Ophthalmology and TherapyVol. 14(12)
Roche (Switzerland) (CH), Gene Therapy Laboratory (FR), Fresno VA Medical Center (US), The California Eye Institute (US), Moorfields Eye Hospital (GB), University College London (GB)
Openalex Percentile: Top 60%
Ophthalmology and Eye Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.